Tissue | Expression Dynamics | Abbreviation |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/TAF1_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/TAF1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/TAF1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/TAF1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000020913 | Endometrium | EEC | protein polyubiquitination | 46/2168 | 236/18723 | 2.65e-04 | 3.04e-03 | 46 |
GO:005109013 | Endometrium | EEC | regulation of DNA-binding transcription factor activity | 75/2168 | 440/18723 | 3.71e-04 | 3.97e-03 | 75 |
GO:001821013 | Endometrium | EEC | peptidyl-threonine modification | 28/2168 | 125/18723 | 4.23e-04 | 4.42e-03 | 28 |
GO:001810713 | Endometrium | EEC | peptidyl-threonine phosphorylation | 26/2168 | 116/18723 | 6.60e-04 | 6.37e-03 | 26 |
GO:007121414 | Endometrium | EEC | cellular response to abiotic stimulus | 58/2168 | 331/18723 | 8.25e-04 | 7.64e-03 | 58 |
GO:010400414 | Endometrium | EEC | cellular response to environmental stimulus | 58/2168 | 331/18723 | 8.25e-04 | 7.64e-03 | 58 |
GO:004668315 | Endometrium | EEC | response to organophosphorus | 26/2168 | 131/18723 | 4.09e-03 | 2.69e-02 | 26 |
GO:000931413 | Endometrium | EEC | response to radiation | 71/2168 | 456/18723 | 5.69e-03 | 3.42e-02 | 71 |
GO:001407415 | Endometrium | EEC | response to purine-containing compound | 28/2168 | 148/18723 | 5.93e-03 | 3.54e-02 | 28 |
GO:00467777 | Endometrium | EEC | protein autophosphorylation | 39/2168 | 227/18723 | 7.52e-03 | 4.21e-02 | 39 |
GO:190331120 | Esophagus | HGIN | regulation of mRNA metabolic process | 91/2587 | 288/18723 | 5.06e-15 | 9.78e-13 | 91 |
GO:000989520 | Esophagus | HGIN | negative regulation of catabolic process | 87/2587 | 320/18723 | 1.74e-10 | 1.68e-08 | 87 |
GO:003133026 | Esophagus | HGIN | negative regulation of cellular catabolic process | 74/2587 | 262/18723 | 6.27e-10 | 5.30e-08 | 74 |
GO:000640120 | Esophagus | HGIN | RNA catabolic process | 77/2587 | 278/18723 | 7.63e-10 | 6.36e-08 | 77 |
GO:000640220 | Esophagus | HGIN | mRNA catabolic process | 67/2587 | 232/18723 | 1.47e-09 | 1.13e-07 | 67 |
GO:003465519 | Esophagus | HGIN | nucleobase-containing compound catabolic process | 98/2587 | 407/18723 | 1.44e-08 | 8.94e-07 | 98 |
GO:004670017 | Esophagus | HGIN | heterocycle catabolic process | 103/2587 | 445/18723 | 5.44e-08 | 2.99e-06 | 103 |
GO:004427018 | Esophagus | HGIN | cellular nitrogen compound catabolic process | 103/2587 | 451/18723 | 1.10e-07 | 5.56e-06 | 103 |
GO:001943917 | Esophagus | HGIN | aromatic compound catabolic process | 105/2587 | 467/18723 | 1.89e-07 | 9.31e-06 | 105 |
GO:190136117 | Esophagus | HGIN | organic cyclic compound catabolic process | 106/2587 | 495/18723 | 1.94e-06 | 7.13e-05 | 106 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TAF1 | SNV | Missense_Mutation | novel | c.3409N>A | p.Gln1137Lys | p.Q1137K | P21675 | protein_coding | deleterious(0.04) | probably_damaging(0.991) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
TAF1 | SNV | Missense_Mutation | novel | c.4912G>A | p.Asp1638Asn | p.D1638N | P21675 | protein_coding | tolerated(1) | benign(0.092) | TCGA-A1-A0SI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TAF1 | SNV | Missense_Mutation | | c.5638N>A | p.Glu1880Lys | p.E1880K | P21675 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.931) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
TAF1 | SNV | Missense_Mutation | novel | c.85N>A | p.Asp29Asn | p.D29N | P21675 | protein_coding | tolerated_low_confidence(0.1) | benign(0.124) | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
TAF1 | SNV | Missense_Mutation | novel | c.4675N>T | p.Pro1559Ser | p.P1559S | P21675 | protein_coding | deleterious(0.01) | possibly_damaging(0.752) | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
TAF1 | SNV | Missense_Mutation | | c.1679G>T | p.Arg560Leu | p.R560L | P21675 | protein_coding | deleterious(0) | benign(0.44) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TAF1 | SNV | Missense_Mutation | | c.4174C>T | p.His1392Tyr | p.H1392Y | P21675 | protein_coding | tolerated(0.17) | benign(0.021) | TCGA-AN-A0AS-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
TAF1 | SNV | Missense_Mutation | | c.2195N>G | p.Asp732Gly | p.D732G | P21675 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-AO-A124-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
TAF1 | SNV | Missense_Mutation | rs760338471 | c.2698A>G | p.Met900Val | p.M900V | P21675 | protein_coding | deleterious(0.03) | benign(0.049) | TCGA-AO-A12F-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
TAF1 | SNV | Missense_Mutation | | c.1816G>A | p.Gly606Arg | p.G606R | P21675 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AR-A1AL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | anastrozole | SD |